Clinical Trial Update: Study of Lanreotide to Treat Polycystic Kidney Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating lanreotide for autosomal dominant polycystic kidney disease, sponsored by University Medical Center Groningen. The current sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Lanreotide (lanreotide)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 3 | Status: UNKNOWN